Amalgam’s Foundation Model for Predictive Patient Intelligence Named Top LLM by the 2026 AI Breakthrough Awards

WILMINGTON, Del.: #clinical--AI Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies, and products in the global Artificial Intelligence (AI) market, today announced that Amalgam Rx, Inc., a leader in enabling data-driven healthcare decision making, has been named the winner of the “Overall Large Language Model of the Year” award in the ninth annual AI Breakthrough Awards program. The honor recognizes Amalgam’s proprietary foundation model for predictive patient intelligence, Chiron, as the most impactful large language model in the global AI industry.

Now in its ninth year, the AI Breakthrough Awards is the longest-running recognition program dedicated exclusively to the AI industry. This year’s program drew more than 5,000 nominations from leading AI companies across more than 20 countries, the most competitive field in the program’s history. Past and present winners include NVIDIA, Snowflake, Intuit, Zapier, Dell Technologies, Deloitte, Qualcomm, AMD, Inflection AI, and many other top companies and startups.

“Most healthcare AI point solutions offer disease-specific models and narrowly scoped decision support tools, addressing only a fraction of the clinical picture. Built on one condition at a time, they require separate data pipelines, training infrastructure, and validation cycles, resulting in a fragmented ecosystem where critical longitudinal patterns across conditions remain invisible,” said Steve Johansson, managing director, AI Breakthrough. “Chiron from Amalgam combines innovative foundation-model architecture, large-scale longitudinal data, and deep clinical integration, transforming healthcare AI into a unified system for predictive patient intelligence.”

Driven by their Medical-Grade AI™, Amalgam’s Chiron is an autoregressive transformer trained on millions of longitudinal, de-identified patient records to predict the next medical event across therapeutic areas. Unlike condition-specific models that require separate data pipelines, training infrastructure, and validation cycles for each disease, Chiron treats the patient journey as a unified sequence of tokenized clinical events: diagnoses, medications, referrals, comorbidities, and demographics. This enables a single model to surface early signals for multiple conditions simultaneously. In sleep apnea alone, Chiron delivered nearly a 2x improvement in diagnostic efficiency compared to traditional tools, identifying the same number of high-risk patients while reducing unnecessary diagnostic follow-ups by nearly half.

Amalgam’s Chiron is designed to be embedded in EHR workflows across major health systems. Predictions can be delivered at the point of care and continuously refined through real-world feedback, a production-grade environment that academic and standalone AI solutions cannot replicate. Amalgam’s partners rely on it to precisely identify patients for therapies and clinical trials, while its adherence risk predictions enable earlier intervention before treatment failure occurs.

“Healthcare AI has been fragmented for too long; one model per condition, one data pipeline per disease, and critical longitudinal patterns falling through the cracks,” said Ryan Sysko, Chief Executive Officer of Amalgam Rx. “We built our model to change that. By learning across the entire patient journey, it gives providers a comprehensive view of risk they’ve never had before and opens a wider window for intervention.”

“What distinguishes Chiron is not just the architecture, but the combination of foundation-model design, large-scale longitudinal data, and deep clinical integration that makes it production-ready,” said Bharath Sudharsan, Chief Data Scientist and Head of AI at Amalgam. “Training on millions of real patient records across therapeutic areas allows us to capture complex temporal relationships that rules-based systems and shallow machine learning simply cannot see. The result is a model that earns trust at the point of care, continuously improving through real-world feedback at a scale no academic or pilot-phase solution can match.”

“AI has the potential to dramatically enhance the way we diagnose and care for patients. Our focus is on the strategic implementation and deployment of this platform-embedding predictive intelligence directly into the EHR workflow to accelerate the treatment journey and deliver better outcomes,” said Azizi A. Seixas, Ph.D., Interim Chair of the Department of Informatics and Health Data Science at the University of Miami Miller School of Medicine and Founder/Director of The Media and Innovation Lab (The MIL). “This initiative directly aligns with The MIL’s vision to pioneer the next generation of healthcare, where tools like this serve as the foundation for an advanced medical AI brain and digital twins for providers. By leading the real-world validation and roll-out of these technologies, we are closing the gap between industry innovation and clinical impact.”

The 2026 AI Breakthrough Award for Overall Large Language Model of the Year continues Amalgam’s track record of recognition for AI innovation in healthcare, building on the company’s 2024 win for Best Large Language Model Application.

About AI Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the AI Breakthrough Awards program is devoted to honoring excellence in Artificial Intelligence technologies, services, companies and products. The AI Breakthrough Awards provide public recognition for the achievements of AI companies and products in categories including Generative AI, Machine Learning, AI Platforms, Robotics, Business Intelligence, AI Hardware, Computer Vision and more. For more information visit AIBreakthroughAwards.com.

About Amalgam Rx

Amalgam reimagines health care by helping patients and providers make the best decisions possible-in the provider workflow and in patients’ everyday lives. For more than 15 years, our team has been reimagining care delivery and creating lasting change across the chronic care ecosystem. Amalgam’s suite of AI-powered EHR Solutions and SaMD platform enable the leading life sciences companies, health plans, and provider organizations to deliver better care collaboratively. Today, Amalgam’s algorithms and applications support patients across four continents and have helped providers make over 50 million clinical decisions. Amalgam’s solutions are powered by billions of RWE streaming data points across its platform. For more information, visit amalgamrx.com.

Fonte: Business Wire